California-based-TP Therapeutics, Inc, a clinical-stage biopharmaceutical company, has raised $45 million in Series C round of funding co-led by China’s Lilly Asia Ventures (LAV), OrbiMed Advisors, LLC, and S.R. One Ltd, the company said in a press release.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com